Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Kaposi's sarcoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: Kaposi's sarcoma. Displaying page 1 of 1.
    EudraCT Number: 2020-004426-36 Sponsor Protocol Number: MK-3475-B60 Start Date*: 2021-05-21
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
    Full Title: A Phase II single-arm study of pembrolizumab plus lenvatinib in previously treated classic Kaposi sarcoma (CKS)
    Medical condition: Advanced unresectable classic Kaposi sarcoma relapsed and/or refractory to previous standard treatments.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023284 Kaposi's sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023284 Kaposi's sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003714-27 Sponsor Protocol Number: P160601J Start Date*: 2017-10-06
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: KAPKEY: Phase II multicentric study of pembrolizumab in classic or endemic Kaposi's sarcoma
    Medical condition: classical and endemic Kaposi's patient with progressive disease,
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023284 Kaposi's sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-000567-26 Sponsor Protocol Number: CKS/IND-CX/05 Start Date*: 2007-07-27
    Sponsor Name:ISTITUTO SUPERIORE DI SANITA`
    Full Title: Phase II Trial for the Treatment of Advanced Classical Kaposi’s Sarcoma with the HIV Protease Inhibitor Indinavir in Combination with Chemotherapy
    Medical condition: patients with advanced Kaposi sarcoma, stage III/IV
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023287 Kaposi's sarcoma classical LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003099-35 Sponsor Protocol Number: SA1001 Start Date*: 2011-11-11
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: Phase I/II study of oral MEK inhibitor Selumetinib (AZD6244 Hyd-Sulphate) in Combination with Highly Active Anti-Retroviral Therapy (HAART) in AIDS-associated Kaposi’s sarcoma (KS).
    Medical condition: AIDS-associated Kaposi's sarcoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023286 Kaposi's sarcoma AIDS related PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000974-22 Sponsor Protocol Number: C06-46 Start Date*: 2008-01-23
    Sponsor Name:Inserm
    Full Title: Essai thérapeutique de phase II séquentiel non randomisé non contrôlé, multicentrique de traitement par everolimus de la maladie de Kaposi classique ou endémique.
    Medical condition: Maladie de Kaposi classique ou endémique
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023287 Kaposi's sarcoma classical LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003745-18 Sponsor Protocol Number: GISG-04 Start Date*: 2012-05-22
    Sponsor Name:University of Heidelberg
    Full Title: A PHASE II WINDOW-OF-OPPORTUNITY STUDY OF PREOPERATIVE THERAPY WITH PAZOPANIB (VOTRIENT®) IN HIGH-RISK SOFT TISSUE SARCOMA
    Medical condition: High-risk soft tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041298 Soft tissue sarcomas histology unspecified HLT
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024628 Liposarcomas malignant HLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024190 Leiomyosarcomas HLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023285 Kaposi's sarcomas HLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001883 Alveolar soft part sarcomas HLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025224 Lymphangiosarcomas HLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039023 Rhabdomyosarcomas HLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016634 Fibrosarcomas malignant HLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029273 Neurofibrosarcomas HLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015100 Epithelioid sarcomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004403-12 Sponsor Protocol Number: APHP190871 Start Date*: 2020-10-26
    Sponsor Name:ASSISTANCE PUBLIQUE DES HOPITAUX DE PARIS
    Full Title: Phase II multicenter study of talimogene laherparepvec in classic or endemic Kaposi sarcoma Kapvec Study
    Medical condition: The study will provide an overview of efficacy and safety of talimogene laherparepvec in classic and endemic KS
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003145-17 Sponsor Protocol Number: TH-CR-406/SARC021 Start Date*: 2012-02-28
    Sponsor Name:Threshold Pharmaceuticals, Inc.
    Full Title: A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced Unresectable or Metastatic Soft Tissue S...
    Medical condition: Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) HU (Completed) PL (Prematurely Ended) BE (Completed) IT (Completed) AT (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003239-38 Sponsor Protocol Number: PH-L19TNFDOX2-03/16 Start Date*: 2017-07-28
    Sponsor Name:Philogen S.p.A.
    Full Title: A Phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patien...
    Medical condition: Unresectable or metastatic soft tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075333 Soft tissue sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-004856-57 Sponsor Protocol Number: IPM2002 Start Date*: 2008-12-31
    Sponsor Name:ZIOPHARM ONCOLOGY, INC
    Full Title: A Phase II multicenter, parallel group, randomized study of palIfosfamide tris plus doxorubiCin versus doxorubicin in subjects with unresectAble or metastatic Soft-tissue SarcOma (PICASSO)
    Medical condition: Unresectable or metastatic soft-tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039491 Sarcoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003648-55 Sponsor Protocol Number: EZH-301 Start Date*: 2020-08-17
    Sponsor Name:Epizyme, Inc.
    Full Title: A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
    Medical condition: Phase 1b: Have histologically confirmed Soft tissue sarcoma (STS). Phase 3: Morphology and immunophenotypic panel consistent with epithelioid sarcoma (eg, CD34, epithelial membrane antigen [EMA], ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015100 Epithelioid sarcomas HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075333 Soft tissue sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) BE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001152-39 Sponsor Protocol Number: SSG XX Start Date*: 2024-05-21
    Sponsor Name:Scandinavian Sarcoma Group
    Full Title: SSGXX A Scandinavian Sarcoma Group treatment protocol for adult patients with non-metastatic high-risk soft tissue sarcoma of the extremities and trunk wall
    Medical condition: SSG XX is a phase II trial for high-risk soft tissue sarcoma(STS) of the extremities and trunk wall. Prognostic markers are used to identify high-risk tumors. SSG XX will evaluate chemo-and radioth...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004104-19 Sponsor Protocol Number: PH-L19TNFSARC-03/18 Start Date*: 2020-02-12
    Sponsor Name:Philogen S.p.A.
    Full Title: A randomized study to investigate the efficacy and safety of the tumor-targeting human antibody-cytokine fusion protein L19TNF in previously treated patients with advanced stage or metastatic soft-...
    Medical condition: Unresectable and/or metastatic soft-tissue sarcoma after failure of at least two prior systemic therapy regimens
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075333 Soft tissue sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000134-30 Sponsor Protocol Number: I5B-MC-JGDJ Start Date*: 2015-09-22
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma
    Medical condition: Advanced or Metastatic Soft Tissue Sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10041298 Soft tissue sarcomas histology unspecified HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) HU (Completed) DE (Completed) ES (Ongoing) AT (Completed) FR (Completed) SE (Ongoing) FI (Completed) BE (Completed) NL (Ongoing) PL (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005506-42 Sponsor Protocol Number: NHL-HIV+ Start Date*: 2007-10-19
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: HIGH-DOSE SEQUENTIAL CHEMOTHERAPY AND RITUXIMAB (R-HDS) IN HIV+ PATIENTS WITH NON-HODGKIN LYMPHOMA (NHL) REFRACTORY OR RELAPSED AFTER 1st LINE TREATMENT
    Medical condition: HIV+ PATIENTS WITH NON-HODGKIN LYMPHOMA (NHL) REFRACTORY OR RELAPSED AFTER 1st LINE TREATMENT
    Disease: Version SOC Term Classification Code Term Level
    10029547 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006041-36 Sponsor Protocol Number: PH-L19IL2TNFBASK-04/21 Start Date*: 2022-02-08
    Sponsor Name:Philogen S.p.A.
    Full Title: A phase II study of L19IL2/L19TNF in patients with skin cancers amenable to intralesional treatment
    Medical condition: Patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention, including: • Basal cell carcinoma (BCC) • Cutaneous squamou...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000441-38 Sponsor Protocol Number: CPCRA 065 Start Date*: 2005-04-26
    Sponsor Name:National Institute of Allergy and Infectious Diseases, National Institutes of Health
    Full Title: Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy (The SMART Study)
    Medical condition: HIV infection
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) IT (Prematurely Ended) IE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Apr 30 23:28:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA